[1] 中华医学会肝病学分会.原发性胆汁性胆管炎的诊断和治疗指南(2021年).临床肝胆病杂志, 2022, 38(1):35-41. [2] Yu H, Robertson ES. Epstein-Barrvirus history and pathogenesis. Viruses, 2023,15(3):714. [3] Lupo J, Truffot A, Andreani J,et al. Virologicalmarkers in Epstein-Barr virus-associated diseases. Viruses, 2023,15(3):656. [4] Morshed SA, Nishioka M, Saito I,et al. Increased expression of Epstein-Barr virus in primary biliary cirrhosis patients. Gastroenterol Jpn, 1992, 27(6):751-758. [5] Rigopoulou EI, Smyk DS, Matthews CE,et al. Epstein-Barr virus as a trigger of autoimmune liver diseases. Adv Virol, 2012, 2012: 987471. [6] Ma G, Yang J, Wang X, et al. Dissecting causal relationships between primary biliary cholangitis and extrahepatic autoimmune diseases based on Mendelian randomization. Sci Rep, 2024,14(1):11528. [7] Huang P, Hou Y, Zou Y,et al. Thecausal effects of primary biliary cholangitis on thyroid dysfunction: A two-sample Mendelian randomization study. Front Genet, 2021,12:791778. [8] Zeng Q, Zhao L, Wang C,et al. Relationship between autoimmune liver disease and autoimmune thyroid disease: a cross-sectional study. Scand J Gastroenterol, 2020,55(2):216-221. [9] Piantanida E, Ippolito S, Gallo D, et al. The interplay between thyroid and liver: implications for clinical practice. J Endocrinol Invest, 2020, 43(7): 885-899. [10] Hayes CM, Gallucci GM, Boyer JL, et al. PPAR agonists for the treatment of cholestatic liver diseases: Over a decade of clinical progress. Hepatol Commun, 2024, 9(1): e0612. |